- Home
- GCTK vs CNSP Comparison
GCTK vs CNSP Comparison
Compare GCTK & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCTK | CNSP |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GCTK | CNSP |
|---|---|---|
| Price | $3.86 | $5.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 75.9K | 21.4K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.21 | $4.93 |
| 52 Week High | $229.44 | $114.00 |
Technical Indicators
Market Signals| Indicator | GCTK | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 39.57 |
| Support Level | $3.21 | $5.20 |
| Resistance Level | $4.21 | $6.17 |
| Average True Range (ATR) | 0.40 | 0.53 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 30.03 | 18.86 |
Price Performance
Historical ComparisonAbout GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.